Connect with us

Featured Stocks

Helix TCS Inc (OTCMKTS: HLIX) Becoming a Cannabis Powerhouse Slowly But Steadily



Helix TCS

The marijuana industry is, without a doubt, a rapidly growing market. However, several regulations keep on changing, and operators highly rely on the most trusted technology solutions to focus their business as well as navigate complexities.

Therefore, only the best stock is what they look after. Likely enough, Helix TCS Inc (OTCMKTS: HLIX) provides the marijuana industry’s most powerful as well as effective critical infrastructure services. Notably, the firm has the market’s leading brands such as BioTrackTHC, Amercanex, Helix Security, and CannaBase with it, which help the company to meet and exceed their requirements.

HLIX 101

Helix TCS Inc. is the leading provider of ancillary services for the marijuana industry in the US. The stock helps owners as well as operators of the licensed marijuana business to stay competitive and compliant as they mitigate risks.

The stock’s products are available to over 2,000 customer locations in almost 33 states and 5 countries. Besides, they have (thus far) processed more than $18 billion in marijuana sales. The numbers may seem impressive, but what lies ahead is somewhat more promising.

HLIX Price Analysis

One area that HLIX stock has not impressed lately is its price, which has been on the downtrend over the past year now. However, it has to be believed that similar market segments have not been very popular in that period, and hence, the declining price tendency may be having last breaths.

Currently, the price of Helix stock stands at $1.68, and it may not be long before we start seeing another upward trajectory. Nevertheless, the stock is off its 52-week high of about $4.01 that it experienced a year ago.

The latest developments, as well as acquisitions the stock has made, may soon prove to be the catalysts for Helix to hit new highs.

HLIX price today.

Helix TCS, Inc. Doing Everything Right for a Breakthrough

In ensuring that the stock remains on track for a breakout, it has thus far made several acquisitions as well as developments. The results of the events may have been highlighted from the report on Helix’s Q1 of 2019.

Preparations for Cannabis as a Commodity

The company has already prepared for cannabis as a commodity by acquiring Amercanex International Exchange. The acquisition is a step further for the stock positioning itself as the leader in the development of modern marijuana market.

Acquired merely two months ago, Amercanex International Exchange is the most influential marijuana electronic trading platforms. Its acquisition provides Helix TCS with a Sophisticated Electronic Communications Network (ECN) which can integrate blockchain technology in facilitating real-time transactions in the market.

It also enables transaction capabilities in several cannabis markets in the US and internationally.

The Contract Extension with Hawaii

Not too long ago, the stock extended its cannabis tracking contract with Hawaii. In the one-year contract, its subsidiary Bio Track THC will be providing the state with medical cannabis traceability system.

Further international Footprint for Helix TCS into Europe: The stock also expanded its reach with licensed cannabis cultivators as well as manufactures in the UK using BioTrackTHC. By doing so they’ll be able to meet the ever-expanding demand in the industry.

The Leading Point of Sale

The company was ranked top revenue-generating ancillary business two months ago by the Cannabis Business Executive. It’s a significant achievement which not only shows that the stock is doing great but also indicates that Helix is on the right track now.

Subsequently, all the developments had shown positive results in the recent Q1 2019 report. If we talk about the numbers, the revenues increased 199% to $3.37 million with a gross profit of $1.45 million, a gross margin of 43%.

What Now for Helix TCS?

As cannabis moves closer to federal legalization in the United States, Helix TCS is one of the best stocks well positioned to proliferate in line with the entire market. With a steady and smart leadership, Helix is poised for way more growth than many think it can.

For the latest updates on HLIX and the hottest MJ stocks, sign up below!

Disclosure: We have no position in HLIX and have not been compensated for this article.

Image courtesy of Pexels

Featured Stocks

Forget APHA and ACB, Buy GTBIF and TCNNF




There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).

On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.

There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.


Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.

Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.

The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…

Continue Reading

Featured Stocks

Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity




Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.

OTCMKTS:DECN Price Analysis

The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.

OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.

DECN Daily Chart

Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.


Decision Diagnostics bills itself…

Continue Reading

Featured Stocks

Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?




CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.

The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.

Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.

About CytoDyn

CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.

Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.

CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment

CytoDyn’s lead drug candidate leronlimab (PRO 140)…

Continue Reading

MJ Stocks